Optimal aspirin dose in acute coronary syndromes: an emerging consensus

Author:

DiNicolantonio James J1,Norgard Nicholas B2,Meier Pascal34,Lavie Carl J56,O’Keefe James H17,Niazi Asfandyar K8,Chatterjee Saurav9,Packard Kathleen A10,D’Ascenzo Fabrizio11,Cerrato Enrico11,Biondi-Zoccai Giuseppe12,Bangalore Sripal13,Fuchs Flavio D14,Serebruany Victor L15

Affiliation:

1. Saint Luke’s Mid America Heart Institute, Kansas City, MO, USA

2. University of Buffalo, School of Pharmacy & Pharmaceutical Sciences, Buffalo, NY, USA

3. The Heart Hospital, University College London Hospitals, London, UK

4. Yale Medical School, New Haven, CT, USA

5. John Ochsner Heart & Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA

6. The Department of Preventive Medicine, Pennington Biomedical Research Center, Baton Rouge, LA, USA

7. University of Missouri, Kansas City, Kansas City, MO, USA

8. Shifa College of Medicine, Islamabad, Pakistan

9. St Luke’s Roosevelt Hospital Center, Division of Cardiology, New York, NY, USA

10. Creighton University, School of Pharmacy & Health Professions, Omaha, NE, USA

11. University of Turin, Division of Cardiology, Citta Della Salute e Della Scienza, Torino, Italy

12. Sapienza University of Rome, Department of Medico-Surgical Sciences & Biotechnologies, Latina, Italy

13. New York University School of Medicine, New York City, NY, USA

14. Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Division of Cardiology & Postgraduate Studies Program in Cardiology, Rio Grande do Sul, Brazil

15. HeartDrug™ Research Laboratories, Johns Hopkins University, Towson, MD, USA

Abstract

ABSTRACT:  Numerous clinical trials testing the efficacy of aspirin for the secondary prevention of cardiovascular disease have been published. We reviewed the literature pertaining to aspirin dose in acute coronary syndrome patients. Clinical trials assessing the comparative efficacy of different doses of aspirin are scarce. This complex antiplatelet therapy landscape makes it difficult to identify the best aspirin dose for optimizing efficacy and minimizing risk of adverse events, while complying with the various guidelines and recommendations. Despite this fact, current evidence suggests that aspirin doses of 75–100 mg/day may offer the optimal benefit:risk ratio in acute coronary syndrome patients.

Publisher

Future Medicine Ltd

Subject

Cardiology and Cardiovascular Medicine,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3